Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2015

View Archived Issues

LECIGon achieves primary endpoint in pivotal E.U. study

Ipsen and OncoDesign disclose LRRK2 inhibitor ODS-2005294

TetraLogic receives FDA clearance to start phase II trial of SHAPE in alopecia areata

TiGenix receives E.U. grant to support trial of Cx-611 in severe sepsis

Antimalarial AQ-13 receives U.S. orphan drug designation

Mitsubishi Tanabe Pharma reviews highlights of second quarter of fiscal 2015

AbbVie describes GlyT1 inhibitor schizophrenia candidate ABT-419

Porcine models used to evaluate stent strategies

Shionogi reviews progress of second quarter of fiscal 2015

Cellectar Biosciences advances PDC chemotherapeutic program

Ironwood Pharmaceuticals begins studies of IW-1973 and IW-1701

Regulus expands development of RG-101

Janssen R&D Ireland reports anti-RSV agents

Jiangsu Hengrui Medicine patents mPGES-1 inhibitors

Gruenenthal introduces Cav2.2 channel blockers

Emory University and Cocrystal Pharma introduce HCV NS5A inhibitors

Shanghai De Novo Pharmatech divulges SGLT2 inhibitors

Novo Nordisk advances pipeline in third quarter 2015

FDA grants priority review to Acadia's NDA for Nuplazid for PD-associated psychosis

Launch of managed access program for Unituxin

CP-628006, novel CFTR potentiator has additive effects with ivacaftor on G551D CFTR function

Sodium and chloride in saliva might be useful biomarkers for CF diagnosis

Sun Pharma completes acquisition of InSite Vision

Boehringer Ingelheim initiates pivotal program for BI-1482694 in NSCLC

MicuRx reports results from second phase II trial of MRX-I in ABSSSI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.